Sonnet Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Sonnet Biotherapeutics Holdings
SONN Stock  USD 1.39  0.03  2.21%   
Sonnet Biotherapeutics financial statements provide useful quarterly and yearly information to potential Sonnet Biotherapeutics Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sonnet Biotherapeutics financial statements helps investors assess Sonnet Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sonnet Biotherapeutics' valuation are summarized below:
Gross Profit
-351.4 K
Market Capitalization
4.3 M
Enterprise Value Revenue
35.9059
Revenue
1000 K
Earnings Share
(10.45)
We have found one hundred twenty available fundamental trend indicators for Sonnet Biotherapeutics Holdings, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sonnet Biotherapeutics' current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 68.9 M. In addition to that, Enterprise Value is likely to drop to about 78.2 M

Sonnet Biotherapeutics Total Revenue

42.64 Million

Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 2.24, Dividend Yield of 0.0 or PTB Ratio of 9.27. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.

Sonnet Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets28.3 M29.8 M17.8 M
Very volatile
Short and Long Term Debt Total9.8 M10.3 M4 M
Pretty Stable
Total Current Liabilities12.4 M13 M7.7 M
Slightly volatile
Property Plant And Equipment Net10.2 M9.8 M5.5 M
Very volatile
Current Deferred Revenue1.1 M1.1 M488.4 K
Slightly volatile
Accounts Payable2.3 M2.4 M3.1 M
Very volatile
Non Current Assets Total27 M28.4 M15.3 M
Very volatile
Net Receivables562.8 K292.8 K436.1 K
Slightly volatile
Liabilities And Stockholders Equity28.3 M29.8 M17.8 M
Very volatile
Non Current Liabilities Total8.1 M8.5 M3.3 M
Pretty Stable
Total Liabilities20.5 M21.5 M10.7 M
Slightly volatile
Total Current Assets1.3 M1.3 M4 M
Pretty Stable
Short Term Debt12.8 M6.7 M3.1 M
Pretty Stable
Common Stock354373324.5 K
Very volatile
Cash497.9 K524.1 K2.9 M
Pretty Stable
Cash And Short Term Investments497.9 K524.1 K2.9 M
Pretty Stable
Other Current Assets151.2 K159.2 K879.1 K
Slightly volatile
Good Will10.1 M12.1 M9.1 M
Slightly volatile
Common Stock Total Equity404426582
Very volatile
Common Stock Shares Outstanding418440347.5 K
Slightly volatile
Property Plant And Equipment Gross5 M9.8 M5.7 M
Pretty Stable
Intangible Assets8.9 M17.3 M9.7 M
Slightly volatile
Warrants297.5 K355.2 K371.8 K
Very volatile
Long Term Debt1.6 M2.7 M3 M
Slightly volatile
Long Term Debt Total1.9 M2.7 M3.2 M
Slightly volatile
Capital Surpluse57.6 M74.5 M54 M
Slightly volatile
Deferred Long Term Liabilities2.1 M3.2 M2.9 M
Pretty Stable
Long Term Investments1.2 M973.2 K1.3 M
Slightly volatile
Non Current Liabilities Other737.3 K776.1 K1.5 M
Very volatile
Property Plant Equipment5.8 M9.4 M8.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity1.1 M744.3 K2.1 M
Slightly volatile
Short and Long Term Debt640673123.9 K
Slightly volatile
Capital Stock55.5858.5838
Very volatile

Sonnet Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1 M1.9 M1.5 M
Very volatile
Selling General Administrative2.4 M2.5 M4.3 M
Pretty Stable
Total Revenue42.6 M40.6 M21.7 M
Pretty Stable
Other Operating Expenses4.5 M4.7 M20.8 M
Pretty Stable
Cost Of Revenue11.8 M7.1 M11.7 M
Pretty Stable
Non Recurring11.5 M10.9 M5.2 M
Slightly volatile
Selling And Marketing Expenses4.2 M4 M2.3 M
Slightly volatile
Preferred Stock And Other Adjustments124.3 K129.1 K113.1 K
Slightly volatile
Research Development2.1 M2.2 M4 M
Slightly volatile

Sonnet Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.1 K5.4 K2.8 M
Pretty Stable
Depreciation2.3 M2.2 M1.4 M
Very volatile
Total Cash From Financing Activities2.1 M2.3 M7.2 M
Pretty Stable
End Period Cash Flow33.9 K35.7 K2.3 M
Pretty Stable
Other Non Cash Items490.4 K516.2 K2.9 M
Slightly volatile
Dividends Paid113.8 K128 K139.6 K
Slightly volatile
Issuance Of Capital Stock2.6 M2.8 M15.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.242.35931.1 M
Slightly volatile
Days Sales Outstanding4.224.44735
Very volatile
Average Payables3.6 M3.7 M9 M
Slightly volatile
Stock Based Compensation To Revenue11.7311.172.8301
Slightly volatile
Capex To Depreciation0.80.842.376
Very volatile
EV To Sales2.542.67861.1 M
Slightly volatile
Payables Turnover11.8811.326.3291
Slightly volatile
Sales General And Administrative To Revenue0.01120.011827.5439
Slightly volatile
Research And Ddevelopement To Revenue0.00480.00532.4047
Slightly volatile
Capex To Revenue0.04730.04970.416
Slightly volatile
Cash Per Share1.1 K1.2 K1.1 K
Pretty Stable
Days Payables Outstanding31.7133.382 K
Pretty Stable
Income Quality0.150.16170.5435
Very volatile
Intangibles To Total Assets0.730.7752.1912
Slightly volatile
Current Ratio0.0980.10320.66
Pretty Stable
Receivables Turnover89.2785.0240.6543
Slightly volatile
Capex Per Share5.6 K4.4 K5.5 K
Pretty Stable
Average Receivables752.3 K460.8 K488 K
Pretty Stable
Revenue Per Share102.2 K69.9 K60.6 K
Pretty Stable
Debt To Assets0.410.3470.8574
Slightly volatile
Days Of Payables Outstanding31.7133.382 K
Pretty Stable
Ebt Per Ebit1.612.62831.4518
Pretty Stable
Long Term Debt To Capitalization0.280.380.1873
Slightly volatile
Net Income Per E B T0.870.761.0258
Pretty Stable
Cash Ratio0.03820.04020.4765
Pretty Stable
Days Of Sales Outstanding4.224.44735
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.392.281.9346
Pretty Stable
Fixed Asset Turnover4.193.15012.6986
Pretty Stable
Debt Ratio0.410.3470.8574
Slightly volatile
Price Sales Ratio2.242.35931.1 M
Slightly volatile
Asset Turnover0.981.0316128
Slightly volatile

Sonnet Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap68.9 M72.5 M167.5 M
Slightly volatile
Enterprise Value78.2 M82.3 M168.6 M
Slightly volatile

Sonnet Fundamental Market Drivers

Cash And Short Term Investments149.5 K

Sonnet Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

About Sonnet Biotherapeutics Financial Statements

Sonnet Biotherapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1.1 M
Total Revenue40.6 M42.6 M
Cost Of Revenue7.1 M11.8 M
Stock Based Compensation To Revenue 11.17  11.73 
Sales General And Administrative To Revenue 0.01  0.01 
Capex To Revenue 0.05  0.05 
Revenue Per Share69.9 K102.2 K
Ebit Per Revenue(0.10)(0.10)
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
How To Invest In Sonnet
Details
Is Sonnet Stock a good investment?
Details
What is Sonnet Biotherapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.45)
Revenue Per Share
0.959
Quarterly Revenue Growth
52.688
Return On Assets
(1.34)
Return On Equity
(2.85)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY